The first includes polymeric carriers that use covalent chemistry for direct drug conjugation (e.g., linear polymers). The second group includes hydrophobic interactions between drugs and ...

PEG-Naloxol (NKTR-118) in Phase II clinical trials. Clinical benefit has already been demonstrated with polymer–drug conjugates bearing classical chemotherapeutic agents. The future of cancer ...

Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with ... phase 2 clinical studies for the treatment of type 2 diabetes. The gastrointestinal (GI) tract ...